Tech

A Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund Its Cancer Programs

Inc.com By Rachel Suleymanov Oct 7, 2026 · 4:57 PM 0 views 0 comments

The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.

Inc.com Original story · www.inc.com

How does this story make you feel?

Discussion (0)

No comments yet. Start the conversation!